Ajanta Pharma Limited has announced that its Board of Directors will convene on November 3, 2025, to deliberate on several key financial matters, including the declaration of the company's first interim dividend for the fiscal year ending March 31, 2026.

Key Points of the Announcement

• Board Meeting Date: November 3, 2025
• Agenda Items:
  • Consider declaring the first interim dividend for FY 2025-26
  • Review unaudited financial results for Q2 and H1 FY 2025-26
  • Potentially fix the record date for dividend payment

Dividend Considerations

The pharmaceutical company has informed the stock exchanges that if an interim dividend is declared, the Board will consider setting November 10, 2025, as the record date for determining shareholder eligibility.

Financial Review

In addition to the dividend deliberation, the Board meeting will focus on reviewing the company's financial performance. The agenda includes:

• Examination of unaudited financial results for the second quarter (Q2) of FY 2025-26
• Review of half-yearly (H1) financial results ending September 30, 2025

Regulatory Compliance

Ajanta Pharma's announcement aligns with regulatory requirements, as stated in their official communication:

"Pursuant to Regulation 29(1)(e) and 42 of the Listing Regulations, we hereby inform you that, at the aforesaid Board Meeting, the Board of Directors will also consider: a. declaration of 1st interim dividend for the financial year ending 31st March 2026; and b. fixation of Monday, 10th November 2025 as the Record Date for the payment of interim dividend, if declared."

Investor Implications

Shareholders and potential investors should mark these dates:

Investors are advised to monitor the outcome of this board meeting, as it may impact the company's stock price and provide insights into Ajanta Pharma's financial health and shareholder return policies.

The company has requested the stock exchanges to disseminate this information to all concerned parties, ensuring transparency and compliance with market regulations.

Ajanta Pharma Limited , a prominent player in the pharmaceutical sector, has seen recent share pledging activities by its promoters. Two key members of the promoter group, Aayush Agrawal and Ravi Agrawal, have disclosed separate transactions involving the pledging of shares for various purposes.

Aayush Agrawal's Share Pledge

Aayush Agrawal, a promoter of Ajanta Pharma Limited, has pledged 6,45,000 shares for new loan and additional margin purposes. The pledge creation was disclosed on October 1, 2025. According to the regulatory filing:

• The Aayush M Agrawal Trust's total encumbered shareholding has increased to 65,80,002 shares, representing 5.27% of the total share capital.
• The pledges were created with multiple financial institutions:
  • Deutsche Investments India Pvt Ltd: 1,20,000 shares for additional margin
  • HSBC InvestDirect Financial Services India Ltd: 70,000 shares for additional margin
  • Jio Finance Ltd: 4,55,000 shares for a new loan

Ravi Agrawal's Share Transactions

In a separate disclosure dated October 3, 2025, Ravi Agrawal, another promoter of Ajanta Pharma, reported both creation and release of pledges:

• Created pledge on 11,52,777 equity shares
• Released pledge on 46,499 equity shares

The reasons cited for these transactions were:

• Creation of pledge: Re-Financing
• Release of pledge: Excess Pledge

Significant transactions in Ravi Agrawal's disclosure include:

• Pledge creation of 10,50,000 shares (0.84% of share capital) with Emerging India Credit Opportunities Fund for business financing on September 30, 2025
• Multiple smaller transactions with various entities including Bajaj Finance Ltd, Barclays Investment, Infina Finance Ltd, and Aditya Birla Capital Limited

Impact on Promoter Holdings

Following these transactions:

• Aayush M Agrawal Trust's encumbered shareholding stands at 65,80,002 shares (5.27% of total share capital)
• Ravi P Agrawal Trust's encumbered shareholding increased to 71,13,920 shares (5.69% of total share capital)

These pledging activities by the promoters are part of their financial management strategies and do not necessarily indicate any immediate change in the company's operations or ownership structure. Investors and market watchers may want to keep an eye on further developments related to promoter shareholdings in Ajanta Pharma Limited.